PMV PHARMACEUTICALS INC's ticker is PMVP and the CUSIP is 69353Y103. A total of 107 filers reported holding PMV PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.42 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,425,701 | +97984.8% | 3,163,795 | 0.0% | 1.03% | +12.6% |
| Q2 2023 | $19,805 | +31.2% | 3,163,795 | 0.0% | 0.92% | +23.9% |
| Q1 2023 | $15,091 | -99.9% | 3,163,795 | 0.0% | 0.74% | -48.9% |
| Q4 2022 | $27,525,016 | -26.9% | 3,163,795 | 0.0% | 1.45% | -31.5% |
| Q3 2022 | $37,649,000 | -24.5% | 3,163,795 | -9.6% | 2.12% | -33.0% |
| Q2 2022 | $49,856,000 | -31.6% | 3,498,636 | 0.0% | 3.16% | -15.7% |
| Q1 2022 | $72,842,000 | +11.1% | 3,498,636 | +23.3% | 3.74% | +47.1% |
| Q4 2021 | $65,563,000 | -3.0% | 2,838,236 | +25.1% | 2.55% | +7.9% |
| Q3 2021 | $67,593,000 | -12.8% | 2,268,236 | 0.0% | 2.36% | -13.7% |
| Q2 2021 | $77,483,000 | +3.9% | 2,268,236 | 0.0% | 2.73% | +8.1% |
| Q1 2021 | $74,602,000 | -46.5% | 2,268,236 | 0.0% | 2.53% | -43.6% |
| Q4 2020 | $139,519,000 | +73.3% | 2,268,236 | 0.0% | 4.48% | +61.2% |
| Q3 2020 | $80,522,000 | – | 2,268,236 | – | 2.78% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Capital LLC | 4,179,416 | $257,076,000 | 54.42% |
| INTERWEST VENTURE MANAGEMENT CO | 6,469,911 | $397,964,000 | 49.71% |
| Octagon Capital Advisors LP | 250,000 | $15,378,000 | 5.33% |
| Boxer Capital, LLC | 2,268,236 | $139,519,000 | 4.48% |
| COMMODORE CAPITAL LP | 125,000 | $7,689,000 | 4.18% |
| Orbimed Advisors | 7,330,423 | $450,894,000 | 3.95% |
| Asymmetry Capital Management, L.P. | 96,595 | $5,942,000 | 2.71% |
| Avoro Capital Advisors LLC | 2,350,267 | $130,536,000 | 2.25% |
| RA Capital Management | 1,710,265 | $105,198,000 | 1.47% |
| HighVista Strategies LLC | 22,654 | $1,393,000 | 0.89% |